Recent advancements in the treatment of HER2-positive metastatic breast cancer are transforming patient outcomes, offering new hope for prolonged survival and even the possibility of cure. The explosion of HER2-targeted therapies—ranging from monoclonal antibodies to antibody-drug conjugates (ADCs) and oral tyrosine kinase inhibitors (TKIs)—has dramatically improved the prognosis for patients battling this aggressive form of cancer. Experts, including Dr. Katherine Crew from Columbia University, emphasize the importance of these developments, which are already extending the lives of patients.
HER2-positive breast cancer accounts for 15% to 20% of all breast cancer diagnoses, with a median survival rate of approximately five years. Historically, treatment options for this subtype have been limited to chemotherapy, endocrine therapy, and HER2-targeted treatments. HER2 (human epidermal growth factor receptor 2) is a protein found in higher than normal amounts in these cancer cells, and its presence has been associated with more aggressive forms of the disease. HER2 testing, often done through immunohistochemistry, helps doctors determine the best course of treatment.
The most well-known HER2-targeted therapies include Herceptin (trastuzumab) and Perjeta (pertuzumab), monoclonal antibodies that block the HER2 protein, along with newer antibody-drug conjugates such as Kadcyla (ado-trastuzumab emtansine) and Enhertu (fam-trastuzumab deruxtecan). Additionally, oral drugs like Tykerb (lapatinib) and Nerlynx (neratinib) provide options for patients who need additional therapies. Dr. Crew highlights clinical trials like CLEOPATRA, DESTINY-Breast01, and HER2CLIMB, which have tested these treatments and demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS).
For example, the CLEOPATRA trial, which tested the addition of Perjeta to Herceptin and chemotherapy, showed a marked improvement in PFS, extending it to 18.5 months compared to just 12.4 months with a placebo. The addition of Perjeta also led to a substantial increase in overall survival rates. However, these therapies are not without side effects, with common issues including diarrhea, alopecia, and neutropenia. In the DESTINY-Breast01 trial, the new drug Enhertu showed a 60.9% objective response rate in patients previously treated with Kadcyla, with a PFS of 16.6 months. The success of Enhertu led to its approval for treating advanced HER2-positive breast cancer.
A major breakthrough came in December 2025 when the FDA approved Enhertu in combination with Perjeta for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. This marks a significant step in extending treatment options and improving outcomes for patients. The approval is based on the strong performance of the drug combination in clinical trials and provides new hope for patients who previously had limited treatment options.
The HER2CLIMB trial, focusing on Tukysa (tucatinib), furthered this momentum by showing that patients who had previously received treatment with Herceptin, Pertuzumab, and Kadcyla saw a median PFS of 7.8 months when treated with Tukysa, compared to just 5.6 months for those on the placebo. The study also included patients with brain metastases—an area previously underserved in clinical trials—and demonstrated that Tukysa offered an improved outcome for these patients, who are typically excluded from many studies due to poor prognosis.
As these HER2-directed therapies continue to show promise, the scope of treatment is also expanding to include HER2-low and ultra-low breast cancer. These forms represent an additional 55% to 60% of breast cancer cases, including aggressive triple-negative cancers. In January 2025, Enhertu was approved for HER2-low or HER2-ultralow breast cancer, offering new hope for patients with limited treatment options. Clinical trials such as DESTINY-Breast04 and DESTINY-Breast06 demonstrated that Enhertu could outperform traditional chemotherapy in these settings, leading to better outcomes for patients with these challenging cancer subtypes.
Looking ahead, these groundbreaking treatments may fundamentally change the landscape of HER2-positive breast cancer care. As research continues to evolve, questions remain about long-term management. For instance, should treatment be stopped if there is no evidence of disease after several years, especially given the high cost and potential side effects of HER2-directed therapies? These are questions that researchers, clinicians, and patients will need to address in the coming years as survival rates continue to improve.
The future of HER2-positive breast cancer treatment is brighter than ever, and thanks to these innovative therapies, more patients are living longer, healthier lives. The journey towards a potential cure is underway, and with ongoing advancements in drug development and clinical trial participation, the fight against metastatic breast cancer has entered a new era.
Related topics:
